ixabepilone

This page shows the latest ixabepilone news and features for those working in and with pharma, biotech and healthcare.

Bayer fails to overturn Nexavar compulsory licence in India

drugs. There have already been suggestions that Roche's breast cancer treatment Herceptin (trastuzumab) and Bristol-Myers Squibb's leukaemia medicine Sprycel (dasatinib) and chemotherapy Ixempra (ixabepilone) could follow Nexavar down

Latest news

India could hit Roche and BMS with compulsory licences

Sprycel (dasatinib) and its chemotherapy Ixempra (ixabepilone).
Triple negative breast cancer

One compound that works via this method is ixabepilone, which binds tubulin and promotes tubulin stabilisation whereby cell division cannot be completed. ... Bristol-Myers Squibb is also investigating ixabepilone in combination with cetuximab in the
Eisai wins approval for breast cancer drug

and with Bristol-Myers Squibb's Ixempra (ixabepilone), which is marketed for patients with late- stage disease after failure of an anthracycline, taxane and Xeloda.
Bristol-Myers signs cancer drug deal

BMS' existing cancer-drug portfolio includes Erbitux (cetuximab), Ixempra (ixabepilone) and Sprycel (dasatinib).
FDA approves BMS chemotherapy drug

The FDA has approved US-based pharmaceutical company Bristol-Myers Squibb's (BMS) new drug to treat advanced breast cancer, Ixempra (ixabepilone).